I'm BRCA Positive but Have No Cancer: — What Happens Now?

No. BRCA positive means your lifetime risk is substantially higher than average, not that cancer is certain. NCCN-cited lifetime breast cancer risk estimates for carriers range from around 45-72% depending on which gene is involved — meaning that a meaningful proportion of carriers will not develop breast cancer over a lifetime even without any intervention. These are population estimates, not individual predictions, and they assume no risk-reducing action is taken. Surveillance and risk-reducing options exist precisely because being a carrier is not a fixed outcome.

Your first-degree relatives — parents, siblings, and adult children — each have a 50% chance of carrying the same variant. Telling them gives them the choice to test and, if positive, to access the same surveillance and risk-reducing options you now have. How and when you tell them is a personal decision. Many people find it helpful to do this through their genetic counsellor, who can advise on how to communicate a result and can provide a letter relatives can take to their own doctor.

Yes. Enhanced surveillance — annual breast MRI and mammogram from your mid-twenties — is itself a risk-management strategy. It does not lower the chance of cancer developing, but it reliably shifts detection earlier, when outcomes are substantially better. Chemoprevention with certain medications is discussed for appropriate candidates under NCCN and ASCO guidance; whether it applies to you depends on your specific situation. Lifestyle measures such as avoiding smoking, limiting alcohol and maintaining a healthy weight are consistent with broader cancer risk guidance, though their effect in BRCA carriers specifically is smaller than the effect of structured surveillance and surgery.

Risk-reducing bilateral mastectomy is surgery to remove both breasts before cancer develops. In BRCA1 and BRCA2 carriers it substantially reduces — though does not eliminate — the lifetime risk of breast cancer. It is one option on a spectrum, not a recommendation that applies to everyone. Many BRCA carriers choose structured surveillance instead and do so effectively for years. The decision depends on your specific variant, your family history, your age, and what weight you personally give to risk reduction versus the impact of surgery. Your team will present the evidence without pushing you toward any particular choice.

These are genuinely nuanced questions and the answers vary by which gene you carry and your complete clinical picture. Combined oral contraceptives are associated with a modest reduction in ovarian cancer risk, which may be relevant for BRCA carriers, and the breast cancer risk implication is actively debated. Hormone replacement therapy after risk-reducing oophorectomy is generally considered appropriate for BRCA carriers who undergo early surgical menopause, according to NCCN guidance, because the ovarian cancer risk has been addressed surgically. Bring all of these questions to your high-risk clinic rather than acting on general guidance — the answers depend on your individual variant and history.

Genetic testing for BRCA1 and BRCA2 is available in India through accredited laboratories, and ICMR guidelines support its use in individuals with a significant family history or other risk factors. If you have already tested positive, the next step is connecting with an oncologist who specialises in hereditary cancer risk. CION coordinates high-risk assessment and surveillance across its network of centres, and any systemic treatment your oncologist recommends can be administered as day care. CAR-T and cell therapy are not services CION provides; if those are ever relevant to your care, your team will refer you to a centre that offers them.